The Characteristics of Literature in Meta-Analyses of Gastrointestinal Symptoms
| Reference . | Age (y) . | Sample size (experiment group/control group) . | Experiment measure/control measure . | Intervention period . | Change in score (experiment group/control group) . | Scale . |
|---|---|---|---|---|---|---|
| Santocchi (2020)32; Italy | 1.5-6 | 31/32 | DSF/placebo | 24 wk | –0.83 (1.89)/–0.09 (1.34)a | 6-GSI |
| Wang (2020)44; China | 2-8 | 7/4 | Probiotic mixture + FOS/placebo | 108 d | –3.44 (1.08)/–1.30 (0.96)a | 6-GSI |
| Emmanuel (2022)50; United Kingdom | 3-16 | 66/66 | Vivomixx/placebo | 12 wk | –0.12 (0.21)/–0.11 (0.21) | GIH |
| Mazzone (2024)48; Italy | 2-8 | 21/22 | L. reuteri/placebo | 24 wk | –2.15 (0.47)/–0.96 (3.25) | GSRS |
| Reference . | Age (y) . | Sample size (experiment group/control group) . | Experiment measure/control measure . | Intervention period . | Change in score (experiment group/control group) . | Scale . |
|---|---|---|---|---|---|---|
| Santocchi (2020)32; Italy | 1.5-6 | 31/32 | DSF/placebo | 24 wk | –0.83 (1.89)/–0.09 (1.34)a | 6-GSI |
| Wang (2020)44; China | 2-8 | 7/4 | Probiotic mixture + FOS/placebo | 108 d | –3.44 (1.08)/–1.30 (0.96)a | 6-GSI |
| Emmanuel (2022)50; United Kingdom | 3-16 | 66/66 | Vivomixx/placebo | 12 wk | –0.12 (0.21)/–0.11 (0.21) | GIH |
| Mazzone (2024)48; Italy | 2-8 | 21/22 | L. reuteri/placebo | 24 wk | –2.15 (0.47)/–0.96 (3.25) | GSRS |
Abbreviations: DSF, a patented mixture (containing 8 probiotic strains, each with 450 billion lyophilized bacteria) already approved for use in children (marketed as Vivomixx® in EU, Visbiome® in USA); FOS, fructo-oligosaccharide; GSI, gastrointestinal severity index; 6-GSI, 6-GI severity index; GIH, gastrointestinal history;
Standard deviation or mean values are not given in the original text and are calculated based on the data provided in Section 16.1.3.2 of the Cochrane handbook based on a correlation coefficient of 0.5.
The Characteristics of Literature in Meta-Analyses of Gastrointestinal Symptoms
| Reference . | Age (y) . | Sample size (experiment group/control group) . | Experiment measure/control measure . | Intervention period . | Change in score (experiment group/control group) . | Scale . |
|---|---|---|---|---|---|---|
| Santocchi (2020)32; Italy | 1.5-6 | 31/32 | DSF/placebo | 24 wk | –0.83 (1.89)/–0.09 (1.34)a | 6-GSI |
| Wang (2020)44; China | 2-8 | 7/4 | Probiotic mixture + FOS/placebo | 108 d | –3.44 (1.08)/–1.30 (0.96)a | 6-GSI |
| Emmanuel (2022)50; United Kingdom | 3-16 | 66/66 | Vivomixx/placebo | 12 wk | –0.12 (0.21)/–0.11 (0.21) | GIH |
| Mazzone (2024)48; Italy | 2-8 | 21/22 | L. reuteri/placebo | 24 wk | –2.15 (0.47)/–0.96 (3.25) | GSRS |
| Reference . | Age (y) . | Sample size (experiment group/control group) . | Experiment measure/control measure . | Intervention period . | Change in score (experiment group/control group) . | Scale . |
|---|---|---|---|---|---|---|
| Santocchi (2020)32; Italy | 1.5-6 | 31/32 | DSF/placebo | 24 wk | –0.83 (1.89)/–0.09 (1.34)a | 6-GSI |
| Wang (2020)44; China | 2-8 | 7/4 | Probiotic mixture + FOS/placebo | 108 d | –3.44 (1.08)/–1.30 (0.96)a | 6-GSI |
| Emmanuel (2022)50; United Kingdom | 3-16 | 66/66 | Vivomixx/placebo | 12 wk | –0.12 (0.21)/–0.11 (0.21) | GIH |
| Mazzone (2024)48; Italy | 2-8 | 21/22 | L. reuteri/placebo | 24 wk | –2.15 (0.47)/–0.96 (3.25) | GSRS |
Abbreviations: DSF, a patented mixture (containing 8 probiotic strains, each with 450 billion lyophilized bacteria) already approved for use in children (marketed as Vivomixx® in EU, Visbiome® in USA); FOS, fructo-oligosaccharide; GSI, gastrointestinal severity index; 6-GSI, 6-GI severity index; GIH, gastrointestinal history;
Standard deviation or mean values are not given in the original text and are calculated based on the data provided in Section 16.1.3.2 of the Cochrane handbook based on a correlation coefficient of 0.5.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
